探讨血清1，5-脱水葡萄糖醇和糖化血清蛋白对妊娠期糖代谢异常的诊断价值

目的探讨糖化血清蛋白（GSP）及1，5-脱水葡萄糖醇（1，5-AG）在妊娠期糖代谢异常诊断中的价值。方法对正常妊娠组、糖筛查异常组及糖耐量异常组进行空腹葡萄糖、口服葡萄糖50g筛选、GSP、1，5-AG测定。结果糖筛查异常组GSP水平为（154±18）μmol／L、糖耐量异常组GSP水平为（157±26）μmol／L，与正常妊娠组[（136±30）μmol／L]比较，差异有统计学意义（P〈0.01）。糖筛查异常组和糖耐量异常组1，5-AG水平分别为（57．3±30．2）μmol／L、（45．2±25．7）μmol／L，显著低于正常妊娠组水平[（84．5±35．6）μmol／L，P〈0．01]。结论GSP、1，5-AG呵作为妊娠期糖代谢异常筛查及诊断指标。     

术前产前及输血前四项传染性指标检测2256例结果分析

目的：探讨孕产妇、手术患者以及输血患者中血液传播性疾病的发病情况及性别年龄分布特点。方法对我院术（产）前、输血前检查的2256例标本传染性指标结果进行回顾性分析。结果 HBsAg阳性139例（6.16%）,男性高于女性（103：36）;抗-TP阳性48例（2.13%）,女性高于男性（29：19）;年龄均以20岁~60岁患者为主,乙肝和梅毒阳性患者性别和年龄分布差异均具有统计学意义（P<0.05）。抗-HCV和抗-HIV阳性率（0.98%,0.27%）均较低,年龄、性别分布差异无统计学意义（P>0.05）。结论术（产）前、输血前传染性指标检查结果可在一定程度上反映出本地区传染病的流行趋势。     

同期经尿道手术治疗浅表性膀胱癌合并前列腺增生的临床疗效观察

目的 观察同期经尿道手术治疗浅表性膀胱癌合并前列腺增生的临床疗效.方法 选取2009年1月～ 2012年3月期间本院接受手术治疗的108例浅表性膀胱癌合并前列腺增生患者.采用随机数表法将108例患者分为观察组和对照组,各54例.观察组患者采用经尿道膀胱电切术(TURBt)+经尿道前列腺切除术(TURP)治疗.对照组患者采用TURBt进行治疗.两组患者术后均给予吡柔比星膀胱内灌注,对比两组患者手术时间、术中出血量、住院时间、术后复发率、残余尿、最大尿流率、尿道狭窄发生率.结果 对照组患者的手术时间、术中出血量、住院时间显著少于观察组患者,两组间比较差异具有统计学意义(P＜0.05).观察组患者的术后复发率、尿道狭窄发生率均低于对照组患者,两组间比较差异具有统计学意义(P＜0.05).两组患者均未发生前列腺部肿瘤种植,观察组患者较对照组患者术后的最大尿流率显著升高,残余尿减少,两组间比较差异具有统计学意义(P＜0.05).结论 同期经尿道手术治疗浅表性膀胱癌合并前列腺增生具有较好的安全性,能够降低术后膀胱癌的复发率,改善患者的排尿情况和生活质量.     

经尿道等离子电切与经膀胱前列腺摘除术治疗大体积前列腺增生的比较

目的：比较经尿道前列腺等离子电切术（PKPR）和经膀胱前列腺摘除术（TVP）治疗大体积（100-150m1）良性前列腺增生（BPH）的安全性和有效性。方法：将100例体积介于100-150ml的BPH患者随机分配到,PKRP组和TVP组。术前分析相关临床资料,术后1个月、3个月、6个月和12个月对患者进行随访,评估指标包括国际前列腺症状评分（IPSS）、生活质量评分（QOL）、最大尿流率（Qmax）和膀胱剩余尿量（PVR）,并记录不良事件。结果：总计有96例患者完成了12个月的随访,PKRP组手术时间较长,但术中失血量少;TVP组虽然有较高的输血率,但腺体切除率占明显优势。PKRP组术后留置导尿管时间、膀胱冲洗时间及住院时间明显缩短。术后1个月,两组的评估指标均得到显著改善,下尿路症状的改善状态在术后12个月内均维持着稳定状态,两组间IPSS、QOL、Qmax和PVR参数并无明显差异。虽然术后两组的并发症发生率较少,但PKRP组的尿道狭窄发生率高于TVP组。结论：对于体积介于100-150ml的BPH患者,PKRP是一种安全有效的治疗方式,能达到传统开放手术的效果。     

Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses

Combinatorial HIV/SIV vaccine approaches targeting multiple arms of the immune system might improve protective efficacy. We compared SIV-specific humoral immunity induced in rhesus macaques by five vaccine regimens. Systemic regimens included ALVAC-SIVenv priming and Env boosting (ALVAC/Env); DNA immunization; and DNA plus Env co-immunization (DNA&Env). RepAd/Env combined mucosal replication-competent Ad-env priming with systemic Env boosting. A Peptide/Env regimen, given solely intrarectally, included HIV/SIV peptides followed by MVA-env and Env boosts. Serum antibodies mediating neutralizing, phagocytic and ADCC activities were induced by ALVAC/Env, RepAd/Env and DNA&Env vaccines. Memory B cells and plasma cells were maintained in the bone marrow. RepAd/Env vaccination induced early SIV-specific IgA in rectal secretions before Env boosting, although mucosal IgA and IgG responses were readily detected at necropsy in ALVAC/Env, RepAd/Env, DNA&Env and DNA vaccinated animals. Our results suggest that combined RepAd priming with ALVAC/Env or DNA&Env regimen boosting might induce potent, functional, long-lasting systemic and mucosal SIV-specific antibodies.     

EIF5A2 Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Growth by Modulating TGF-β Signals

Anaplastic thyroid carcinoma (ATC) is resistant to standard therapies and has no effective treatment. Eukaryotic translation initiation factor 5A2 (EIF5A2) has shown to be upregulated in many malignant tumors and proposed to be a critical gene involved in tumor metastasis. In this study, we aimed to investigate the expression status of EIF5A2 in human ATC tissues and to study the role and mechanisms of EIF5A2 in ATC tumorigenesis in vitro and in vivo. Expression of EIF5A2 protein was analyzed in paraffin-embedded human ATC tissues and adjacent nontumorous tissues (ANCT) (n = 24) by immunochemistry. Expressions of EIF5A2 mRNA and protein were analyzed in fresh-matched ATC and ANCT (n = 23) and ATC cell lines by real-time polymerase chain reaction (PCR) and Western blotting. The effect of targeting EIF5A2 with short hairpin RNA (shRNA) or EIF5A2 overexpression on the ATC tumorigenesis and TGF- /Smad2/3 signals in vitro and in vivo was investigated. Expression of EIF5A2 was significantly upregulated in ATC tissues and cell lines compared with ANCT and normal follicular epithelial cell line. Functional studies found that targeting EIF5A2 induced SW1736 cell death in vitro and in vivo, followed by significantly downregulated phosphorylation of Smad2/3 (p-Smad2/3) in SW1736 cells at the protein level. Ectopic expression of EIF5A2 could promote 8505C cell growth in vitro and in vivo, followed by significantly upregulated p-Smad3 at the protein level. Recombinant human TGF- 1 (hTGF- 1) treatment decreased the antiproliferative activity of the EIF5A2 downexpressing 8505C cells through reversing pSmad2/3. Using the specific inhibitor SB431542 to block TGF- pathway or Smad3 siRNA to knock down Smad3 increased the antiproliferative activity of the EIF5A2-overexpressing 8505C cells through inhibiting pSmad2/3. Our findings indicated that EIF5A2 controled cell growth in ATC cells, and EIF5A/TGF- /Smad2/3 signal may be a potential therapeutic target for ATC treatment.     

Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer

Background  

Insulin-like growth factor-I receptor (IGFIR) has been shown to regulate the tumor development. The objective of the current study is to determine the association of IGFIR with lymph node metastasis and to explore the related mechanism in human colorectal cancer in clinic.     

经尿道电切术治疗射精管梗阻引起的无精子症

目的进一步探讨由于射精管梗阻(EDO)引起的无精子症的治疗。方法采用精液分析(包括精液的量、pH值、果糖的测定)、经直肠指检、B超检查精囊腺,手法检查和B超检查附睾的方法诊断。于2004年11月至2006年12月,20例患者临床上诊断为因射精管梗阻引起的无精子症,采用经尿道电切术切开、切除梗阻的射精管,直至见到有乳白色、褐色、黄褐色或暗红色精液排出。结果20例无精子症患者的精液量增多,精液中出现精子,1年内精液分析连续3次正常,其中4例其配偶怀孕。5例患者术后1年复查精囊腺明显缩小。本组没有发现明显的并发症。结论经尿道电切术治疗射精管梗阻的无精子症是一种简单、有效的方法。